Research programme: antibody radionucleotide conjugates - Nordic Nanovector/Paul Scherrer Institute
Alternative Names: NNV 011; NNV 013Latest Information Update: 28 May 2020
At a glance
- Originator Nordic Nanovector; Paul Scherrer Institut
- Class Antineoplastics; Immunoconjugates; Radiopharmaceuticals
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leukaemia
Most Recent Events
- 28 May 2020 No recent reports of development identified for research development in Leukaemia in Norway
- 28 May 2020 No recent reports of development identified for research development in Leukaemia in Switzerland